Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Research Coverage on Small and Micro-Cap Companies

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Equity Bottom-Up

<ul><li>Dyadic has developed C1, its proprietary fungal expression system that can produce a variety of recombinant proteins.</li><li>C1 has been commercialized in industrial applications and is in development for production of pharmaceutical grade proteins.</li><li>C1 exhibits potential to economically produce recombinant proteins, biologic vaccines, virus-like particles, antibodies, Fc-fusion, enzymes, AAVs and other biopharmaceuticals.</li></ul>

Dyadic has developed C1, its proprietary fungal expression system that can produce a variety of recombinant proteins.C1 has been commercialized in industrial applications and is in development for production of pharmaceutical grade proteins.C1 exhibits potential to economically produce recombinant proteins, biologic vaccines, virus-like particles, antibodies, Fc-fusion, enzymes, AAVs and other biopharmaceuticals.

DYAI: Layers of Commercialization Agreements

<ul><li>Dyadic has developed C1, its proprietary fungal expression system that can produce a variety of recombinant proteins.</li><li>C1 has been commercialized in industrial applications and is in development for production of pharmaceutical grade proteins.</li><li>C1 exhibits potential to economically produce recombinant proteins, biologic vaccines, virus like particles, antibodies, Fc-fusion, enzymes, AAVs and other biopharmaceuticals.</li></ul>

Dyadic has developed C1, its proprietary fungal expression system that can produce a variety of recombinant proteins.C1 has been commercialized in industrial applications and is in development for production of pharmaceutical grade proteins.C1 exhibits potential to economically produce recombinant proteins, biologic vaccines, virus like particles, antibodies, Fc-fusion, enzymes, AAVs and other biopharmaceuticals.

United States

Dyadic International, Inc. is a global biotechnology company. The Company focuses on improving and applying the proprietary C1 expression system to help drug developers and manufacturers bring biologic drugs to market. Dyadic International focuses on drugs that will improve access and cost to patients as well as save lives.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Dyadic International (DYAI US)

DYAI: First Quarter Results

Dyadic has developed C1, its proprietary fungal expression system that can produce a variety of recombinant proteins. C1 has been commercialized...

Zacks Small Cap Research

DYAI: Introducing AlbuFree DX

Dyadic has developed C1, its proprietary fungal expression system that can produce a variety of recombinant proteins. C1 has been commercialized...

Zacks Small Cap Research

DYAI: Layers of Commercialization Agreements

Dyadic has developed C1, its proprietary fungal expression system that can produce a variety of recombinant proteins. C1 has been commercialized...

Zacks Small Cap Research

DYAI: Purchase Orders Rolling In

Dyadic has developed C1, its proprietary fungal expression system that can produce a variety of recombinant proteins. C1 has been commercialized...

Zacks Small Cap Research

DYAI: One Strain To Rule Them All

Dyadic has developed C1, its proprietary fungal expression system that can produce a variety of recombinant proteins. C1 has been commercialized...

Zacks Small Cap Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)